Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Queensland Health
AstraZeneca
Federal Trade Commission
Farmers Insurance
Teva
Chinese Patent Office
Cipla
Johnson and Johnson

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,486,456

« Back to Dashboard

Which drugs does patent 8,486,456 protect, and when does it expire?

Patent 8,486,456 protects ONMEL and is included in one NDA.

This patent has eight patent family members in five countries.
Summary for Patent: 8,486,456
Title:Itraconazole compositions with improved bioavailability
Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>.DELTA.H.sub.tr (1) (wherein .DELTA.H.sub.tr represents the endotherm (J/g) accompanying a transition at about 240.degree. C). The solid dispersion product shows an improved bioavailability.
Inventor(s): Berndl; Gunther (Herheim am Berg, DE), Degenhardt; Matthias (Limburgerhof, DE), Maegerlein; Markus (Mannheim, DE), Dispersyn; Gerrit (Pennington, NJ)
Assignee: Abbott GmbH & Co., KG (Wiesbaden, DE)
Application Number:11/997,256
Patent Claim Types:
see list of patent claims
Compound; Formulation; Dosage form; Use;

Drugs Protected by US Patent 8,486,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sebela Ireland Ltd ONMEL itraconazole TABLET;ORAL 022484-001 Apr 29, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,486,456

PCT Information
PCT FiledAugust 08, 2006PCT Application Number:PCT/EP2006/007839
PCT Publication Date:February 15, 2007PCT Publication Number: WO2007/017248

Non-Orange Book US Patents Family Members for Patent 8,486,456

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,149,431 Itraconazole compositions with improved bioavailability ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Daiichi Sankyo
Colorcon
McKesson
Johnson and Johnson
Harvard Business School
AstraZeneca
Julphar
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.